Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
1998-06-10
2009-02-24
Landsman, Robert S. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C530S389200
Reexamination Certificate
active
07494652
ABSTRACT:
Compositions and methods are described for treatment of sepsis in animals, including humans. Unique and specific combinations of polyclonal antibodies directed to cytokines are shown to have a beneficial effect in animal models predictive of human therapy.
REFERENCES:
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5420253 (1995-05-01), Emery et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5585098 (1996-12-01), Coleman et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5747532 (1998-05-01), Lai
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: WO 9108774 (1991-06-01), None
patent: WO 96/33204 (1996-10-01), None
patent: WO 9814209 (1998-04-01), None
patent: WO 9814209 (1998-04-01), None
Starnes et al. Anti-IL-6 monoclonal antibodies protect against lethalE. coliinfection and lethal TNF-alpha challenge in mice, Juornal of Immunology, vol. 145, No. 12, pp. 4185-4191, Dec. 1990.
Doherty et al. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and TNF alpha, Journal of Immunology, vol. 149, No. 5, pp. 1666-1670, Sep. 1992.
Beutler B. et al. Science 299;869-871 Aug. 30, 1985.
WebMD listing of symptoms of AIDS: http://www.webmd.com/hw/hiv—aids/hw151445.asp.
Machiedo et al., “Patterns of Mortality in a Surgical Intensive Care Unit,”Surg. Gyn.&Obstet.152:757-759 (1981).
Morris et al., “Endotoxemia in neonatal calves given antiserum to a mutantEscherichia coli(J-5),”Am. J. Vet. Res.47:2554-2565 (1986).
Hoffman et al., “Prognostic Variables for Survival of Neonatal Foals Under Intensive Care,”J. Vet. Int. Med.6:89-95 (1992).
Wolff, “Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock,”New Eng. J. Med.324:486-488 (1991).
K.A. Schulman et al., “Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis,”JAMA266:3466-3471 (1991).
K. Ohlsson et al., “Interleukin-1 receptor antagonist reduces mortality from endotoxin shock,”Nature348:550-552 (1990).
R.C. Bone, “The Pathogenesis of Sepsis,”Ann. Intern. Med.115:457-469 (1991).
K.J. Tracey et al., “Shock and Tissue Injury Induced by Recombinant Human Cachectin,”Science234:470-474 (1986).
A. Tewari et al., “Preliminary report: effects of interleukin-1 on platelet counts,”Lancet336:712-714 (1990).
S.M. Opal et al., “Efficacy of a Monoclonal Antibody Directed against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection withPseudomonas aeruginosa,” J. Infect. Dis.161:1148-1152 (1990).
Polson et al., “Antibodies to Proteins from Yolk of Immunized Hens,”Immunol. Comm., 9:495 (1980).
C. Galanos et al., “Galactosamine-induced sensitization to the lethal effects of endotoxin,”Proc. Natl. Acad. Sci. USA76:5939-5943 (1979).
J. Rothe et al.“Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes,”Nature364:798-802 (1993).
S.Q. DeJoy et al., “Effect of CL 184,005, a Platelet-Activating Factor Antagonist in a Murine Model ofStaphylococcus auteus-Induced Gram-Positive Sepsis,”J. Infect. Dis.169:150-156 (1994).
Opal et al., “Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock,”J. of Infectious Diseases173:1415-1421 (1996).
Russell et al., “Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function,”J. of Infectious Diseases171:1528-1538 (1995).
Plevy et al., “A Role for TNF-α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease,”J. of Immunology159:6277-6282 (1997).
Van Dullemen et al., “Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenterology109:129-138 (1995).
Targan et al., “A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease,” NEJM, 337:1029-1035 (1997).
Elliott et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis,”Lancet344:1105-1110 (1994).
Elliott et al., “Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis,”Lancet344:1125-1127 (1994).
Kojouharoff et al., “Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice,”Clin Exp Immunol107:353-358 (1997).
Olson et al., “Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis,”J Ped Gastroenterology Nutrition21:410-418 (1995).
Zacharchuk et al., “Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor,”PNAS USA80:6341-6345 (1983).
Zacharchuk, Charles Michael, “A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization,” Dissertation Abstract.
Pennica et al., “Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin,”Nature312:724-729 (1984).
Ruff, Michael Roland, “Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor,” Dissertation Abstract.
Doherty et al., “Evidence for IFN-γ as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor-α,”J. Immunology149(5):1666-1670 (1992).
Manthey et al., “The role of cytokines in host responses to endotoxin,”Reviews in Medical Microbiology3(2):72-79 (1992).
Starnes et al., “Anti-IL-6 Monoclonal Antibodies Protect Against LethalEscherichia coliInfection and Lethal Tumor Necrosis Factor-α challenge in mice,” J. of Immun. 145(12):4185-4191 (1990).
Hissong Bruce D
Landsman Robert S.
Medlen & Carroll LLP
Promega Corporation
LandOfFree
Treatment of sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of sepsis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134718